PUMA
10.4.2024 10:01:29 CEST | Business Wire | Press release
Global sports company PUMA has launched its first worldwide brand campaign in 10 years “FOREVER. FASTER. - See The Game Like We Do” with the objective to strengthen PUMA’s positioning as the Fastest Sports Brand in the world. The campaign conveys the brand’s unique connection with speed and invites everyone - professional and everyday athletes alike - to see the game like PUMA does.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410842258/en/
Global sports company PUMA has launched its first worldwide brand campaign in 10 years “FOREVER. FASTER. - See The Game Like We Do” (Photo: Business Wire)
PUMA was founded in 1948 by Rudolf Dassler who had the vision to create shoes that make athletes agile, nimble and fast – just like a puma. Over the last 75 years, PUMA has worked with the fastest athletes, clubs and federations in the world to create cutting-edge innovations that provide sporting excellence and victories that live forever in the memories of fans across the globe.
This year – through the globally featured Brand Campaign - PUMA is demonstrating how speed has always been deeply rooted in the brand’s DNA. Speed has always been PUMA’s vantage point. The desire to be faster and overtake others is in everyone’s nature. To go faster gives you joy and an adrenaline rush like no other. The passion for speed is simply universal. “See The Game Like We Do: FOREVER. FASTER.” means to see sports and sports culture differently and ultimately win in a way only the fastest can. In a way only PUMA can. PUMA has always been able to be the first to see the next play, quick to act on its instinct, and set the pace for others to follow. This is what enables us to see the game differently, challenge conventions and create moments that will live with us forever.
“Everyone dreams of having a superpower and speed is PUMA’s,” said Arne Freundt, CEO of PUMA. “Speed is the superpower the greats use to change the game. Just like our world icons Mondo Duplantis, Karsten Warholm, Neymar Jr or Breanna Stewart, we know that speed unlocks athletic performance and victory in everyone. Through our ability to bring speed to life, PUMA invites all people to break through their own limits, unlock their personal best and become a better version of themselves, allowing them to see the game like we do: FOREVER. FASTER.”
“Our new global brand campaign is PUMA’s biggest marketing investment ever,” said Richard Teyssier, Vice President Brand and Marketing. “It is the first time that PUMA has one single message – FOREVER. FASTER. - throughout the entire year and across all performance categories such as Football, Running, Basketball and Handball. The holistic brand message is emotional and distinctive to make sure it connects and resonates with our target consumers.”
“FOREVER. FASTER. - See The Game Like We Do” launches on April 10 and will be communicated across the entire media mix, such as Social Media, TV, PR, Out Of Home Media and Points of Sale worldwide. It will include a hero brand film and supporting creative assets with featured top athletes, such as Antoine Griezmann, Breanna Stewart, Christian Pulisic, Felix Streng, Jack Grealish, Javier “Chicharito” Hernández, Karsten Warholm, Kai Havertz, Lamelo Ball, Luis Suarez, Memphis Depay, Mondo Duplantis, Neymar Jr., Sergio Aguero, Shericka Jackson, Yaroslava Mahuchikh and many others. Later this year, PUMA will present dedicated brand videos and creative assets for The CONMEBOL Copa America, UEFA Euro 2024, and The 2024 Summer Olympics.
Brand film, long version: https://youtu.be/LRJP140fv3E
Brand film, short version: https://youtu.be/OmQGUQNQkwk
Images: Link
PUMA |
PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410842258/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom